The U.S. Supreme Court hears arguments today in the FTC v. Actavis case, on “reverse payments” in pharmaceutical cases. IPO filed a brief in support of Actavis. IPO’s brief said, “the presumption of illegality that [the Federal Trade Commission] would attach to so-called reverse payment patent settlements would have a substantial negative impact on innovation in the pharmaceutical industry and beyond.”
